Asset Details
Do you wish to reserve the book?
Digital intervention mylovia improves sexual functioning in women with sexual dysfunction in randomized controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Digital intervention mylovia improves sexual functioning in women with sexual dysfunction in randomized controlled trial
Do you wish to request the book?
Digital intervention mylovia improves sexual functioning in women with sexual dysfunction in randomized controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Digital intervention mylovia improves sexual functioning in women with sexual dysfunction in randomized controlled trial
2026
Overview
Given the widespread issue of female sexual dysfunction and the scarcity of treatment options, novel therapeutic approaches are needed. This randomized controlled trial evaluated the use of
mylovia
©
, a self-guided digital intervention for female sexual dysfunction and sexual pain disorder based on CBT and mindfulness, in addition to treatment as usual (TAU) compared to TAU plus information material. 252 women participated. At three months, the intervention group showed significantly greater improvements (Cohen’s
d
= 0.51,
p
< 0.001) in sexual functioning, measured by the Female Sexual Function Index (FSFI), with effects maintained at six months. Clinical relevance was confirmed by Reliable Change Index (RCI) responder analysis. The intervention group also reported greater improvements in sexual desire, satisfaction, and pain-related cognitions and behaviors. There were no significant between-group differences in depressive symptoms or adverse events. The intervention demonstrated comparable efficacy to existing psychosocial treatments, offering a digital therapeutic that could narrow the current gender healthcare gap. This trial was registered on ClinicalTrials.gov on 24 January 2024, with the identifying number NCT06237166.
